Hepatitis A virus IgG (HAV-IgG) ELISA Kit

Short Description:

Hepatitis A virus (HAV) is the causative agent of hepatitis A. It is transmitted via the fecal-oral route and often manifests as an asymptomatic infection, primarily affecting children and young adults. Infection with HAV leads to acute liver inflammation, which may involve hepatocyte damage and focal necrosis, with a recovery period that can extend from several weeks to months. While the infection is generally self-limiting without progressing to chronic disease, it can pose significant health risks during the acute phase, including fatigue and potential complications in severe cases.

The body produces anti-HAV IgG antibodies in response to infection or vaccination, regardless of whether the infection is symptomatic or asymptomatic. Anti-HAV IgG antibodies typically appear within a few weeks after the onset of infection, rising to detectable levels by 3-12 weeks, and persist for many years or lifelong. They confer immunity against reinfection with HAV and serve as a marker of past infection or acquired immunity (e.g., from prior infection or vaccination). In certain clinical scenarios, paired serum samples demonstrating a significant rise (e.g., fourfold or greater) in anti-HAV IgG titer can aid in confirming recent infection when other markers are inconclusive.

Send email to us

Product Detail

Product Tags

Principle:

This kit employs the indirect enzyme-linked immunosorbent assay (ELISA) principle to detect hepatitis A virus IgG antibodies (anti-HAV IgG) in human serum or plasma samples. The polystyrene microwell strips are pre-coated with hepatitis A virus antigens. Upon addition of the serum or plasma specimen, any anti-HAV IgG antibodies present in the sample bind specifically to the immobilized antigens, while unbound components are removed by washing. In the subsequent step, horseradish peroxidase (HRP)-conjugated mouse anti-human IgG antibodies are added, which bind to the captured human IgG. Following another wash to remove unbound HRP conjugates, a chromogenic substrate (TMB) is added to the wells. In the presence of the antigen - anti-HAV IgG - HRP-anti-human IgG immunocomplex, the HRP enzyme catalyzes the substrate reaction, producing a blue color that is proportional to the concentration of anti-HAV IgG. The reaction is halted by adding a stop solution (typically 50 μL per well), which shifts the color to yellow. The absorbance (optical density) is then measured using a microplate reader at the appropriate wavelength (e.g., 450 nm) to determine the presence and level of anti-HAV IgG antibodies in the sample.

Product Features:

High sensitivity, specificity and stability

Product Specification:

Principle	Enzyme linked immunosorbent assay
Type	Indirect Method
Certificate	NMPA
Specimen	Human serum / plasma
Specification	48T / 96T
Storage temperature	2-8℃
Shelf life	12 months